Pemetrexed versus erlotinib in pretreated patients with advanced non-small cell lung cancer: A Hellenic Oncology Research Group (HORG) randomized phase 3 study
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Pemetrexed versus erlotinib in pretreated patients with advanced non-small cell lung cancer: A Hellenic Oncology Research Group (HORG) randomized phase 3 study
Authors
Keywords
-
Journal
CANCER
Volume 119, Issue 15, Pages 2754-2764
Publisher
Wiley
Online
2013-05-09
DOI
10.1002/cncr.28132
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study
- (2012) Tudor Ciuleanu et al. LANCET ONCOLOGY
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
- (2012) Rafael Rosell et al. LANCET ONCOLOGY
- Prospective Molecular Marker Analyses ofEGFRandKRASFrom a Randomized, Placebo-Controlled Study of Erlotinib Maintenance Therapy in Advanced Non–Small-Cell Lung Cancer
- (2011) Wolfram Brugger et al. JOURNAL OF CLINICAL ONCOLOGY
- Anaplastic Lymphoma Kinase Gene Rearrangements in Non-small Cell Lung Cancer are Associated with Prolonged Progression-Free Survival on Pemetrexed
- (2011) D. Ross Camidge et al. Journal of Thoracic Oncology
- Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
- (2011) Caicun Zhou et al. LANCET ONCOLOGY
- Randomized Phase III Trial of Gefitinib versus Docetaxel in Non-Small Cell Lung Cancer Patients Who Have Previously Received Platinum-Based Chemotherapy
- (2010) D. H. Lee et al. CLINICAL CANCER RESEARCH
- Epidermal Growth Factor Receptor-Related Tumor Markers and Clinical Outcomes with Erlotinib in Non-small Cell Lung Cancer: An Analysis of Patients from German Centers in the TRUST Study
- (2010) Claus-Peter Schneider et al. Journal of Thoracic Oncology
- Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
- (2010) Makoto Maemondo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Molecular Predictors of Outcome With Gefitinib and Docetaxel in Previously Treated Non–Small-Cell Lung Cancer: Data From the Randomized Phase III INTEREST Trial
- (2009) Jean-Yves Douillard et al. JOURNAL OF CLINICAL ONCOLOGY
- Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
- (2009) Tetsuya Mitsudomi et al. LANCET ONCOLOGY
- KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: A meta-analysis of 22 studies
- (2009) Chen Mao et al. LUNG CANCER
- Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
- (2009) Rafael Rosell et al. NEW ENGLAND JOURNAL OF MEDICINE
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- (2009) Tony S. Mok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC
- (2008) A Kalikaki et al. BRITISH JOURNAL OF CANCER
- Role ofKRASandEGFRAs Biomarkers of Response to Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21
- (2008) Chang-Qi Zhu et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Study, V-15-32, of Gefitinib Versus Docetaxel in Previously Treated Japanese Patients With Non–Small-Cell Lung Cancer
- (2008) Riichiroh Maruyama et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
- (2008) Giorgio Vittorio Scagliotti et al. JOURNAL OF CLINICAL ONCOLOGY
- Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial
- (2008) Edward S Kim et al. LANCET
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation